Clinical Trials

Cancer Type: Bladder

Hospitals offering this trial

 

2009-485
CALGB 90601: A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma.

This study is for patients with advanced transitional cancer of the urinary tract (bladder cancer). The purpose of this study is to compare the effects of the combination of the chemotherapy drugs gemcitabine and cisplatin with the combination of gemcitabine, cisplatin, and the experimental drug bevacizumab to find out which is better. Bevacizumab is an antibody that we think can block a protein called VEGF and inhibit the growth of new blood vessels. Bevacizumab has been approved by the FDA for the treatment of metastatic colorectal, lung, and breast cancer, but for transitional cell carcinoma, it is not FDA-approved and should be considered experimental.

The combination of gemcitabine and cisplatin is one commonly used treatment that has been shown to make some patients with transitional cell carcinoma live longer. This research is being dome to see if adding bevacizumab to gemcitabine and cisplatin will delay the growth of the cancer and allow patients to live longer.

Lombardi/MedStar Georgetown University Hospital; Washington Hospital Center

Forms:

 

Contact : Karen Vogel
Email: KD252@georgetown.edu
Phone: 202-687-6974